Page last updated: 2024-11-04

risedronic acid and Heart Disease, Ischemic

risedronic acid has been researched along with Heart Disease, Ischemic in 1 studies

Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.

Research Excerpts

ExcerptRelevanceReference
"Comorbid factors such as ischemic heart disease, hip osteoarthritis, and higher values of FRAX blunted the effects of QOL of the treatment."1.38The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study. ( Hayakawa, Y; Iinuma, N; Itoh, M; Iwayama, S; Kamisaki, T; Nakamura, T; Nishikawa, M; Osawa, M; Suzuki, H; Yamaguchi, H, 2012)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nakamura, T1
Osawa, M1
Itoh, M1
Yamaguchi, H1
Iinuma, N1
Hayakawa, Y1
Suzuki, H1
Kamisaki, T1
Iwayama, S1
Nishikawa, M1

Other Studies

1 other study available for risedronic acid and Heart Disease, Ischemic

ArticleYear
The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study.
    Journal of bone and mineral metabolism, 2012, Volume: 30, Issue:6

    Topics: Aged; Aged, 80 and over; Asian People; Bone Density; Bone Density Conservation Agents; Comorbidity;

2012